Painless, Non-Invasive
Skin Cancer Therapy

Learn More

Bringing back Quality of Life

Single Session

Need an Appointment?

Has COVID-19 changed or postponed your Skin Cancer treatment date?

With the Rhenium-SCT Referral Program we connect you with the nearest treatment center.

Rhenium-SCT Referral Program:

request the next possible treatment date here.



The Rhenium-SCT (Skin Cancer Therapy) is a specialized state-of-the-art brachytherapy utilizing the radioisotope Rhenium-188, a beta-emitter which in this case is used for the treatment of basal and squamous cell carcinomas of the skin.

188W/188Re Generator

Production of high-energy beta emitting 188Re

Various sizes available

up to 150GBq (4Ci) 188W

High activity concentration

up to 9GBq/ml

Variable elution volume

Elution volume of 5-14 ml (partial elution for small volumes)

Low breakthrough

188W < 0.01 % in relation to 188Re at calibration time

Who we are

OncoBeta GmbH is a pioneer in the radioisotope sector, presently offering an innovative Skin Cancer Therapy targeting non-melanoma skin cancers and producing Tungsten (Wolfram)-188/Rhenium-188 (W/Re-188) Generators for commercial use.

Recent Events

COVID-19: We are here for you.

To our Valued Patients, Customers and Health Care providers, As we navigate through these trying times surrounding the Coronavirus (COVID-19)...
Read More

OncoBeta Announces Approval and ARTG Listing of Rhenium-SCT (Rhenium-188 paste) in Australia for the treatment of skin cancer lesions and skin tumors

Further Regulatory Submissions Ongoing
OncoBeta® GmbH and their subsidiary OncoBeta Therapeutics Pty Ltd. Australia a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanoma Skin Cancers (NMSCs), announced today that the Rhenium-SCT (Rhenium-188 paste) has been registered on the Australian Register of Therapeutic Goods (ARTG), which is the formal requirement for supply and marketing of the medical device.
Read More

OncoBeta GmbH and Australian Nuclear Science and Technology Organisation sign Letter of Intent to establish manufacturing site in Australia

Innovative medical device Rhenium-SCT therapy for Non-Melanoma Skin Cancer to be produced in Australia
Read More

Group RPH and OncoBeta GmbH sign agreement for Sales Referral and Distribution of Rhenium-SCT® in Brazil.

Grupo RPH is now the Official Rhenium-SCT® Sales Representative and Distributor in Brazil for the treatment of Non-Melanoma Skin Cancer.
Read More

Personalized irradiation therapy for NMSC by rhenium-188 skin cancer therapy: a long-term retrospective study

Abstract Objectives This study aimed to provide long-term clinical data about an innovative epidermal radioisotope therapy called Rhenium-SCT® (Skin Cancer...
Read More

China Isotope & Radiation Corporation (CIRC) and OncoBeta sign distribution agreement for Tungsten 188/Rhenium-188 generators

Beijing, China and Garching near Munich, Germany, Tuesday 30th June 2020. CIRC and OncoBeta today announced that they have signed an agreement for the distribution of high energy beta particle W/Re-188 generators in China.
Read More

How can you Reduce the Risk of Skin Cancer?

Skin Cancer is the most common type of cancer in the world 1. Ultraviolet (UV) Radiation exposure is one of...
Read More

B.J. Madan & Co India and OncoBeta announce exclusive distribution agreement for W/Re-188 generators.

New Delhi, India and Garching near Munich, Germany, 6th March, 2020. B.J Madan & Co and OncoBeta announced the execution...
Read More

RadioMedix and OncoBeta announce exclusive distribution agreement for W/Re-188 generators in U.S. and Canada.

RadioMedix and OncoBeta today announced the execution of an exclusive distribution agreement for the next generation of W/Re-188 generators in the U.S. and Canada.
Read More

Oncobeta chosen as one of the Trailblazing Companies to Watch in 2019

OncoBeta- A Pioneer And Innovator In The Epidermal Radioisotope Therapy Sector Skin is the largest organ of the body and...
Read More